Factors associated with longer endocrine therapy use by South Carolina Medicaid-insured breast cancer survivors.

Bedi, Julie S; Mayo, Rachel M; Chen, Liwei; Dickes, Lori; Sherrill, Windsor W; Jones, Karyn

Bedi, Julie S; Mayo, Rachel M; Chen, Liwei; Dickes, Lori; Sherrill, Windsor W; Jones, Karyn.

Afiliación

Bedi JS; Department of Public Health Sciences, Clemson University, Clemson, SC, USA.
Mayo RM; Department of Public Health Sciences, Clemson University, Clemson, SC, USA.
Chen L; Department of Public Health Sciences, Clemson University, Clemson, SC, USA.
Dickes L; Department of Parks, Recreation, and Tourism Management, Clemson University, Clemson, SC, USA.
Sherrill WW; Department of Public Health Sciences, Clemson University, Clemson, SC, USA.
Jones K; Department of Public Health Sciences, Clemson University, Clemson, SC, USA.

J Oncol Pharm Pract ; 26(1): 36-42, 2020 Jan.

Article en En | MEDLINE | ID: mdl-30885081

Asunto(s)

Antineoplásicos Hormonales/uso terapéutico; Neoplasias de la Mama/tratamiento farmacológico; Neoplasias de la Mama/epidemiología; Medicaid/tendencias; Sobrevivientes; Adulto; Inhibidores de la Aromatasa/uso terapéutico; Neoplasias de la Mama/diagnóstico; Quimioterapia Adyuvante/tendencias; Esquema de Medicación; Femenino; Humanos; Persona de Mediana Edad; South Carolina/epidemiología; Tamoxifeno/uso terapéutico; Estados Unidos/epidemiología; Adulto Joven

Palabras clave

Endocrine therapy; Tamoxifen; aromatase inhibitors; breast cancer; cancer surviorship

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Medicaid / Sobrevivientes / Antineoplásicos Hormonales Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged País/Región como asunto: America do norte Idioma: En Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google